Product Reports Resources Pricing Login Book a demo

Ironwood Pharmaceuticals

Biotech & Life Sciences · Boston, United States · Founded 1998 · IPO 2010

We are committed to advancing the treatment of GI diseases and redefining the standard of care for GI patients

Valuation $1.07B
Revenue $460M
EBITDA $326M

Investors

5 investors on Ironwood Pharmaceuticals's cap table

Sourced from Dealroom's funding history. Investor profile links are shown where available.

Series A 1 investor entered at this stage
Series B+ 4 investors entered at this stage

Global footprint

Where Ironwood Pharmaceuticals has talent and traffic

Workforce by country
11 countries with
team presence
🇺🇸 United States79.3%
🇨🇭 Switzerland11.8%
🇪🇸 Spain1.6%
🇬🇧 United Kingdom1.5%
🇧🇪 Belgium1%
Top 5 of 11 shown
Web traffic by country
9.1K monthly visits
across markets
🇺🇸 United States69.2%
🇬🇧 United Kingdom11%
🇮🇳 India8.8%
🇨🇭 Switzerland4.4%
🇹🇷 Turkey4.4%
Top 5 markets shown

Talent graph

The shape of Ironwood Pharmaceuticals's talent

Dealroom maps Ironwood Pharmaceuticals's team person by person — pinpointing the standout operators and scoring them across the six dimensions investors underwrite. The counts and shape below are a public preview; the named individuals and exact scores live in the platform.

9 standout operatorsDealroom-flagged across the org
2 AI specialistsincl. 1 core researchers
261 employees mappedperson by person
DimensionScore
AI Talentlive Score hidden — book a demo
Engineering Score hidden — book a demo
Product Score hidden — book a demo
Go-to-market Score hidden — book a demo
Leadership Score hidden — book a demo
Research Score hidden — book a demo
Book a demo to unlock Ironwood Pharmaceuticals's exact scores

Source: Dealroom Talent Intelligence. Public profiles show counts and the team's shape only — request a demo for the named individuals, per-person seniority and tenure, and team benchmarks vs peers.

Patent intelligence

$107M patent portfolio · 52 active families

Estimated portfolio value
$107M
10.0% of market cap · 1.5× larger than top peer Aerie Pharmaceuticals ($71M)
52 active patent families
Where Ironwood Pharmaceuticals innovates DiseaseGastrointestinal disorderGastroparesisLinaclotideMedicinal chemistry

Where Ironwood Pharmaceuticals concentrates vs peers

Each axis is a top-10 topic across Ironwood Pharmaceuticals and its closest peers. #1 = 100, #10 = 10, absent = 0.

Compare against

Source: Dealroom Patent Intelligence · Patsnap. Request a demo for the full per-sub-category breakdown, individual records, and quality-score history.

Market sentiment

What the market is saying about Ironwood Pharmaceuticals

An AI-synthesized read of the highest-engagement posts about Ironwood Pharmaceuticals on X over the past 7 days. We rank by likes & retweets, ignore corporate channels, and surface the themes that broke out from real people.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Ironwood Pharmaceuticals on the full Dealroom platform

Live deal flow, founder pedigree, hiring signals, revenue trajectory, and the full cap table.